Paul A Antony

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells
    Paul A Antony
    Division of Surgery, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 174:2591-601. 2005
  2. pmc IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells
    Christopher A Klebanoff
    Howard Hughes Medical Institute National Institutes of Health Research Scholars Program, Bethesda, MD 20814, USA
    Proc Natl Acad Sci U S A 101:1969-74. 2004
  3. pmc CTLA-4 dysregulation of self/tumor-reactive CD8+ T-cell function is CD4+ T-cell dependent
    Luca Gattinoni
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Mark O Hatfield Clinical Research Center, 10 Center Drive, Room 3 5750, Bethesda, MD 20892, USA
    Blood 108:3818-23. 2006
  4. pmc Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling
    Chrystal M Paulos
    National Cancer Institute NCI, NIH, Bethesda, Maryland 20892 1502, USA
    J Clin Invest 117:2197-204. 2007
  5. pmc Interleukin-2-dependent mechanisms of tolerance and immunity in vivo
    Paul A Antony
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 176:5255-66. 2006
  6. pmc Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells
    Luca Gattinoni
    Center for Cancer Research, National Cancer Institute NCI, National Institutes of Health NIH, Bethesda, MD 20892, USA
    J Exp Med 202:907-12. 2005
  7. pmc Toll-like receptors in tumor immunotherapy
    Chrystal M Paulos
    National Cancer Institute, NIH, Mark O Hatfield Clinical Research Center, Bethesda, Maryland 20892 1502, USA
    Clin Cancer Res 13:5280-9. 2007
  8. pmc Tumor-specific Th17-polarized cells eradicate large established melanoma
    Pawel Muranski
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Mark O Hatfield Clinical Research Center, Bethesda, MD 20892, USA
    Blood 112:362-73. 2008
  9. pmc Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells
    Willem W Overwijk
    National Cancer Institute NCI, National Institute of Health, Bethesda, MD 20892 1502, USA
    J Exp Med 198:569-80. 2003
  10. pmc Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells
    Christopher A Klebanoff
    Howard Hughes Medical Institute, National Institutes of Health Research Scholars Program, Bethesda, MD 20814, USA
    Proc Natl Acad Sci U S A 102:9571-6. 2005

Detail Information

Publications17

  1. pmc CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells
    Paul A Antony
    Division of Surgery, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 174:2591-601. 2005
    ..These findings reveal that Th cells can help break tolerance to a persisting self-Ag and treat established tumors through an IL-2-dependent mechanism, but requires simultaneous absence of naturally occurring T(reg) cells to be effective...
  2. pmc IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells
    Christopher A Klebanoff
    Howard Hughes Medical Institute National Institutes of Health Research Scholars Program, Bethesda, MD 20814, USA
    Proc Natl Acad Sci U S A 101:1969-74. 2004
    ..These results provide several avenues for improving adoptive immunotherapy of cancer in patients...
  3. pmc CTLA-4 dysregulation of self/tumor-reactive CD8+ T-cell function is CD4+ T-cell dependent
    Luca Gattinoni
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Mark O Hatfield Clinical Research Center, 10 Center Drive, Room 3 5750, Bethesda, MD 20892, USA
    Blood 108:3818-23. 2006
    ..These results indicated that CD8(+) CLTA-4(-/-) T-cell-mediated autoimmunity and tumor immunity required CD4(+) T cells in which the function was dysregulated by the absence of CTLA-4-mediated negative costimulation...
  4. pmc Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling
    Chrystal M Paulos
    National Cancer Institute NCI, NIH, Bethesda, Maryland 20892 1502, USA
    J Clin Invest 117:2197-204. 2007
    ..Thus, disruption of the homeostatic balance between the host and microbes can enhance cell-based tumor immunotherapy...
  5. pmc Interleukin-2-dependent mechanisms of tolerance and immunity in vivo
    Paul A Antony
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 176:5255-66. 2006
    ..Lastly, administration of anti-IL-2 plus exogenous IL-15 to tumor-bearing mice enhanced the adoptive immunotherapy of cancer. Therefore, Th cell-derived IL-2 paradoxically controls both tolerance and immunity to a tumor/self-Ag in vivo...
  6. pmc Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells
    Luca Gattinoni
    Center for Cancer Research, National Cancer Institute NCI, National Institutes of Health NIH, Bethesda, MD 20892, USA
    J Exp Med 202:907-12. 2005
    ..Thus, the restricted availability of homeostatic cytokines can be a contributing factor to peripheral tolerance, as well as a limiting resource for the effectiveness of tumor-specific T cells...
  7. pmc Toll-like receptors in tumor immunotherapy
    Chrystal M Paulos
    National Cancer Institute, NIH, Mark O Hatfield Clinical Research Center, Bethesda, Maryland 20892 1502, USA
    Clin Cancer Res 13:5280-9. 2007
    ..We also discuss alternate regimens to chemotherapy or TBI, which might be used to safely treat patients with advanced disease and promote tumor regression...
  8. pmc Tumor-specific Th17-polarized cells eradicate large established melanoma
    Pawel Muranski
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Mark O Hatfield Clinical Research Center, Bethesda, MD 20892, USA
    Blood 112:362-73. 2008
    ..This principle should be considered in designing clinical trials involving adoptive transfer-based immunotherapy of human malignancies...
  9. pmc Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells
    Willem W Overwijk
    National Cancer Institute NCI, National Institute of Health, Bethesda, MD 20892 1502, USA
    J Exp Med 198:569-80. 2003
    ....
  10. pmc Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells
    Christopher A Klebanoff
    Howard Hughes Medical Institute, National Institutes of Health Research Scholars Program, Bethesda, MD 20814, USA
    Proc Natl Acad Sci U S A 102:9571-6. 2005
    ..Thus, tumor-reactive CD8+ T cell populations with the phenotypic and functional attributes of T(CM) may be superior to T(EM)/effector T cells for adoptive immunotherapies using concomitant tumor-antigen vaccination...
  11. pmc IL-2 and IL-15 each mediate de novo induction of FOXP3 expression in human tumor antigen-specific CD8 T cells
    Mojgan Ahmadzadeh
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunother 30:294-302. 2007
    ....
  12. pmc Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer
    Steven E Finkelstein
    National Cancer Institute, National Institutes of Health, Building 10, Room 2B 46, 10 Center Drive, Bethesda, MD 20892, USA
    J Leukoc Biol 76:333-7. 2004
    ..Complete responders frequently develop autoimmunity with vitiligo at the former tumor site that often spreads to involve the whole coat. These findings have important implications for the design of immunotherapy trials in humans...
  13. pmc Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy
    Christopher A Klebanoff
    Howard Hughes Medical Institute National Institutes of Health Research Scholars Program, Bethesda, MD 20814, USA
    Trends Immunol 26:111-7. 2005
  14. pmc Th17 cells are long lived and retain a stem cell-like molecular signature
    Pawel Muranski
    National Cancer Institute, Bethesda, MD 20892, USA
    Immunity 35:972-85. 2011
    ..Thus, Th17 cells are not always short lived and are a less-differentiated subset capable of superior persistence and functionality...
  15. pmc Assumptions of the tumor 'escape' hypothesis
    Nicholas P Restifo
    National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Semin Cancer Biol 12:81-6. 2002
    ..The dysregulation characteristic of the transformed genome is also what makes tumor immunity, a specialized form of autoimmunity, possible...
  16. ncbi request reprint Intestinal intraepithelial lymphocyte gamma delta-T cell-derived keratinocyte growth factor modulates epithelial growth in the mouse
    Hua Yang
    Section of Pediatric Surgery, Department of Surgery, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    J Immunol 172:4151-8. 2004
    ..These results show that KGF from IELs is an important factor for maintenance of intestinal epithelial cell proliferation and villus growth...
  17. pmc Interferon-gamma expression by intraepithelial lymphocytes results in a loss of epithelial barrier function in a mouse model of total parenteral nutrition
    Hua Yang
    Section of Pediatric Surgery, The University of Michigan Medical School and C S Mott Children s Hospital, Ann Arbor, Michigan, USA
    Ann Surg 236:226-34. 2002
    ..To determine the etiology of the loss of epithelial barrier function observed with the administration of total parenteral nutrition (TPN) in a mouse model...